In patients with NSCLC, measuring the percentage of PD-L1-positive cancer cells in cancer tissues by immunohistochemistry (IHC) is useful for predicting the efficacy and application of anti-PD-1 and -PD-L1 therapeutic antibodies [7–9]. Here, CD274 is linked to non-small cell lung carcinoma.